Welcome to our dedicated page for PRECIGEN SEC filings (Ticker: PGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Precigen, Inc. filings document the company’s biopharmaceutical operations, commercial product disclosures, governance matters, and capital structure. Form 8-K reports cover financial results, PAPZIMEOS business updates, investor presentations, commercial supply arrangements, and financing agreements tied to the company’s transition into commercial-stage operations.
Precigen’s proxy materials describe board elections, auditor ratification, executive compensation votes, and equity incentive plan matters. Other filings disclose its Nasdaq-listed common stock, preferred-stock conversion activity, senior secured debt arrangements, material agreements, risk factors, and corporate governance controls relevant to a public precision-medicine company.
PRECIGEN, INC. (PGEN) director Jeffrey B. Kindler reported selling 185,000 shares of common stock on 2026-08-26 in an open market or private transaction. The weighted average sale price was $7.44 per share, with individual trades executed between $7.38 and $7.59. Following this sale, Kindler directly holds 17,100 shares of Precigen common stock.
PRECIGEN, INC. (PGEN) is the issuer for which Jeffrey Kindler has filed a notice of proposed sale of restricted securities under Rule 144. The filing covers 185,000 shares of Common Stock, with an indicated aggregate market value of $1,372,700, to be sold through Goldman Sachs & Co. LLC on or after 08/26/2026. These shares were acquired from Precigen as compensation in the form of Restricted Stock Units on various grant dates between 03/09/2023 and 03/13/2026.
PRECIGEN, INC. (PGEN) director Nancy H. Agee purchased 3,411 shares of Common Stock in an open-market or private transaction on 2026-08-21 at a price of $7.23 per share. Following this transaction, she directly owns 309,187 shares of PRECIGEN common stock.
PRECIGEN, INC. (PGEN) reported that Chief Legal Officer Donald P. Lehr had 5,208 Restricted Stock Units granted on June 26, 2025 vest on August 23, 2026, converting into an equal number of common shares. To cover income tax withholding, 2,488 shares were withheld at $7.20 per share, leaving a net increase of 2,720 shares. Following these transactions, Lehr directly holds 57,292 shares of Precigen common stock.
PRECIGEN, INC. (PGEN) reported that Chief Financial Officer Harry Thomasian Jr. settled a portion of previously granted Restricted Stock Units (RSUs) on August 23, 2026. He exercised 7,291 RSUs, each convertible into one share of common stock, receiving an equal number of common shares in connection with the vesting of 1/24 of an RSU grant made on June 26, 2025.
To satisfy income tax withholding obligations arising from this RSU settlement, 3,577 shares of Precigen common stock were withheld at a value of $7.20 per share, reported as a code F disposition. Following these transactions, Thomasian directly held 80,209 RSUs. The filing does not report any open-market purchases or sales; reported dispositions relate to tax withholding.
PRECIGEN, INC. (PGEN) reported that Chief Operating Officer Rutul R. Shah exercised stock options and RSUs and sold common shares. On August 21 and 25, 2026, he exercised options for a total of 50,000 shares at $2.33 per share and sold 50,000 shares at $7.50 per share pursuant to a Rule 10b5-1 trading plan. On August 23, 2026, 7,500 RSUs converted into common stock, and 3,647 shares were withheld to satisfy tax obligations, leaving 57,292 RSUs outstanding.
PRECIGEN, INC. (PGEN) reported that Chief Commercial Officer Phil Tennant exercised stock awards and sold shares in August 2026. On August 25, he exercised options to acquire 79,166 shares of common stock at an exercise price of $1.61 per share, reducing that option grant to 120,834 options remaining, and received 79,166 common shares. That same day, he sold 79,166 shares of common stock at $7.50 per share pursuant to a Rule 10b5-1 trading plan.
On August 23, 5,208 Restricted Stock Units vested and converted into the same number of common shares, representing 1/24 of an RSU grant made on June 26, 2025; 57,292 RSUs remained after this vesting. Also on August 23, 2,585 shares were withheld at a price of $7.20 per share to satisfy income tax withholding obligations in connection with the RSU settlement.
PRECIGEN, INC. (PGEN) reported that President and CEO Helen Sabzevari exercised 20,833 Restricted Stock Units into an equal number of shares of common stock on August 23, 2026. The RSUs represent 1/24 of a grant made on June 26, 2025 that vested on that date. Of the resulting shares, 10,184 shares were withheld at $7.20 per share to satisfy income tax withholding obligations. Following the transaction, Sabzevari held 229,167 RSUs directly.
PRECIGEN, INC. (PGEN) is named as the issuer in a Form 144 notice filed for the planned sale of its common stock by officer Rutul Shah. The notice covers a proposed sale of 15,342 common shares, with an approximate value of $115,065.00, to be sold through Fidelity Brokerage Services LLC on or after 08/25/2026, following a stock option exercise for cash. Over the prior three months, the same person reported several additional sales of PRECIGEN common shares under Rule 144.
PRECIGEN, INC. (PGEN) received a Rule 144 notice relating to a potential sale of its common stock. An officer, Phillip Tennant, has filed to sell up to 79,166 shares of PRECIGEN common stock through Fidelity Brokerage Services LLC on or after 08/25/2026 on NASDAQ. The shares are tied to a stock option exercise paid in cash and have an aggregate market value of $593,745.00 as stated in the notice.